The Orissa Minerals Development Co. (NSE:ORISSAMINE, BOM:590086) named M N V S Prabhakar as its new non-executive chairman, effective May 25, according to an Indian bourse filing on Tuesday.
Shares of the company rose 1% in Wednesday's trade.
He currently heads Rashtriya Ispat Nigam as chairman and managing director.
Prabhakar succeeds Manish Raj Gupta, who held additional charge as chairman and managing director of Rashtriya Ispat Nigam, the filing said.
Cynata Therapeutics (ASX:CYP) said the results for the Australian phase three SCUlpTOR trial of its CYP-004 drug candidate in patients with osteoarthritis of the knee are expected in June, according to a Wednesday Australian bourse filing.The trial enrolled a total of 321 patients, who were randomized to receive either CYP-004 or placebo, with co-primary endpoints assessing change in pain and cartilage thickness, the filing said. The study database was locked, and the process of data analysis is ongoing.The results for the company's phase two trial of its CYP-001 drug candidate in adults with acute graft versus host disease are anticipated in late June or early July.A total of 65 participants were enrolled across clinical centers in Australia, the US, and Europe, randomized to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint is overall response rate at Day 28.The company's shares rose nearly 6% in recent trading on Wednesday.
China Merchants Securities (HKG:6099, SHA:600999) appointed Zhu Jiangtao as chairman effective Tuesday, according to a same-day Hong Kong bourse filing.Hong Kong-listed shares of the financial firm were down 1% in Wednesday's midday trade.Zhu formally stepped down from his role as president on Tuesday to facilitate the transition.The company said it will appoint a new president as soon as practicable, with Zhu temporarily maintaining double duties during the vacancy.
Jointown Pharmaceutical (SHA:600998) unit Shandong Jingfeng passed China's generic drug consistency evaluation for trihexyphenidyl hydrochloride tablets.The anticholinergic drug is used to treat Parkinson's patients and for antipsychotic-induced extrapyramidal reactions, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 2% in recent trade.